Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy skies hovering over the Pharmalot campus. After all, as the Morning Mayor used to say: Every brand new day should be unwrapped like a precious gift. Toward that end, we are celebrating as our shortest person turns another page on the calendar of life. This calls for a few cups of stimulation. Our choice today is Jack Daniel’s. Yes, this is real. Meanwhile, here are a few items of interest. Hope you have a smashing day and do keep in touch …

A controversial treatment for preventing premature births will be reviewed by an FDA panel on Tuesday amid intensifying debate over whether the medication, called Makena, should remain on the market, STAT says. The panel is set to review a required followup study that found the medicine was not effective, a troublesome development given that Makena is the standard of care. The results called into question the extent to which physicians should continue to use the medicine and prompted intense betting on Wall Street about what the FDA will do.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!